Roots Analysis has done a detailed study on Global Autoinjectors Market (3^rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link

 

Key Market Insights

• Currently, several companies claim to be engaged in the development / manufacturing of various types of autoinjectors, most of which are disposable systems that use prefilled syringes as primary drug containers
• About 90 autoinjector-based combination products have been approved for the treatment of a variety of clinical conditions; the subcutaneous route being the preferred mode of drug delivery via such devices
• In order to gain a competitive edge in the market, many autoinjector manufacturers are focusing on the integration of advanced features into their respective products and affiliated offerings
• Over time, more than 4,600 patents have been filed / granted related to autoinjectors and affiliated products; most of the new intellectual property is related to additional features, such as safety locks and device connectivity
• Eminent scientists from renowned organizations and academic institutions across the world have made valuable contributions to this field, in terms of leading clinical research efforts and developing novel technologies
• Several autoinjector developers have established strong brand positions in different geographies; the focus, in the near term, is likely to be on further enhancing device features for better disease management and improved patient compliance
• An evaluation of 200+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via autoinjectors in the near future
• Case Study: Owing to the complexities associated with the manufacturing and assembly of autoinjector drug delivery systems, industry players are known to frequently engage the services of contract service providers
• Currently, disposable autoinjector products for small molecule drugs dominate the market; however, in the foreseen future, the demand for reusable devices is anticipated to witness significant growth
• Given the recent approvals and presence of multiple drug candidates in later stages of development, the market opportunity is likely to be distributed across different therapeutic areas, routes of administration and geographies

 

For more information, please visit  https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html

 

Table of Contents

 

1.              PREFACE

1.1.           Scope of the Report

1.2.           Research Methodology

1.3.           Chapter Outlines

 

2.              EXECUTIVE SUMMARY

                

3.              INTRODUCTION

3.1.           Chapter Overview

3.2.           Types of Drug Delivery Systems

3.3.           Drawbacks of Conventional Parenteral Delivery Systems

3.4.           Needlestick Injuries

3.4.1.        Incidence and Cost Burden

3.4.2.        Government Legislation for the Prevention of Needlestick Injuries           

                

3.5.           Emerging Trend of Self-Administration

3.5.1.        Rising Burden of Chronic Diseases

3.5.2.        Healthcare Cost Savings

3.5.3.        Need for Immediate Treatment in Emergency Situations

3.5.4.        Growth of Injectable Biologics Market

3.5.5.        Addressing Key User Safety Requirements

                

3.6.           Types of Self- Administration Devices

3.6.1.        Prefilled Syringes

3.6.2.        Pen-Injectors

3.6.3.        Needle-Free Injectors

3.6.4.        Autoinjectors

3.6.5.        Large Volume Wearable Injectors

                

3.7.           Overview of Autoinjectors

3.7.1.        Components of Autoinjectors

3.7.2.        Classification of Autoinjectors

3.7.2.1.      On the Basis of Mechanism of Action

3.7.2.2.      On the Basis of Usability

3.7.2.3.      On the Basis of Type of Dose

3.7.3.        Manufacturing / Packaging of Autoinjectors

3.7.4.        Benefits of Autoinjectors

                

3.8.           Regulatory Considerations

3.8.1.        Medical Devices

3.8.2.        Drug Device Combination Products

 

3.9.           Future Perspectives

                

4.              PRIMARY DRUG CONTAINERS

4.1.           Chapter Overview

4.2.           Types of Packaging

4.3.           Introduction to Primary Drug Containers

4.3.1.        Role of Primary Drug Containers

4.3.2.        Types of Primary Drug Containers

4.3.2.1.      Cartridges

4.3.2.1.1.   Components of Cartridges

4.3.2.1.2.   Types of Cartridges

4.3.2.1.2.1.  Single Chamber Cartridge

4.3.2.1.2.2.  Dual Chamber Cartridge

4.3.2.1.3.   Cartridges Available in the Market

                

4.3.2.2.      Syringes

4.3.2.2.1.   Components

4.3.2.2.2.   Types of Syringes

4.3.2.2.2.1.  Based on Number of Chambers

4.3.2.2.2.2.  Based on Type of Needle

4.3.2.2.3.   Prefilled Syringe Systems Available in the Market

4.3.2.2.3.1.  Glass Prefilled Syringes

4.3.2.2.3.2.  Plastic Prefilled Syringes

                

4.3.2.3.      Vials

4.3.2.3.1.   Components

4.3.2.3.2.   Vials Available in the Market

 

4.4.           Comparison of Fabrication Materials

                

5.              AUTOINJECTORS: CURRENT MARKET LANDSCAPE

5.1.           Chapter Overview

5.2.           Autoinjectors: List of Devices

5.2.1.        Analysis by Usability

5.2.2.        Analysis by Type of Primary Container

 

5.3.           Autoinjectors: List of Additional Parameters of Devices

5.3.1.        Analysis by Volume of Container

5.3.2.        Analysis by Type of Dose

5.3.3.        Analysis by Route of Administration

5.3.4.        Analysis by Actuation Mechanism

5.3.5.        Analysis by Type of Feedback Mechanism

                

5.4.           Autoinjectors: List of Developers

5.4.1.        Analysis by Year of Establishment

5.4.2.        Analysis by Company Size

5.4.3.        Analysis by Geographical Location of Headquarters

                

6.              PRODUCT COMPETITIVENESS ANALYSIS

6.1.           Chapter Overview

6.2.           Methodology

6.3.           Assumptions and Key Parameters

6.4.           Product Competitiveness Analysis

6.4.1.        Disposable Autoinjectors

6.4.2.        Reusable Autoinjectors

                

7.              BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS

7.1            Chapter Overview

7.2.           Scope and Methodology

7.3.           Brand Positioning Matrix: Antares Pharma

7.4.           Brand Positioning Matrix: BD

7.5.           Brand Positioning Matrix: DALI Medical Devices

7.6.           Brand Positioning Matrix: Elcam Drug Delivery Devices

7.7.           Brand Positioning Matrix: Oval Medical Technologies

7.8            Brand Positioning Matrix: Owen Mumford

7.9.           Brand Positioning Matrix: SHL Medical

7.10          Brand Positioning Matrix: Union Medico

7.11.         Brand Positioning Matrix: Ypsomed

                

8.              PATENT ANALYSIS

8.1.           Chapter Overview

8.2.           Scope and Methodology

8.3.           Autoinjectors: Patent Analysis

8.3.1.        Analysis by Application Year

8.3.2.        Analysis by Issuing Authority

8.3.3.        Analysis by CPC Symbols

 

8.4.           Emerging Areas

8.5.           Leading Players Based on Number of Patents

8.6.           Autoinjectors: Patent Benchmarking Analysis

8.6.1.        Analysis by Patent Characteristics

8.6.2.        Analysis by Geography

 

8.7.           Autoinjectors: Patent Valuation Analysis

                

9.              THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS

9.1.           Chapter Overview

9.2.           Autoinjector Combination Products: List of Approved Drugs

9.2.1.        Analysis by Initial Year of Approval

9.2.2.        Analysis by Usability

9.2.3.        Analysis by Route of Administration

9.2.4.        Analysis by Primary Drug Container

 

9.3.           Approved Autoinjector Combination Products: List of Additional Parameters

9.3.1.        Analysis by Type of Molecule

9.3.2.        Analysis by Dose Strength

9.3.3.        Analysis by Therapeutic Indication

9.3.4.        Analysis by Other Packaging Formats of Marketed Drugs

 

9.4.           Autoinjector Combination Products: List of Pipeline Drugs

9.4.1.        Analysis by Phase of Development

 

9.5.           Pipeline Autoinjector Combination Products: List of Additional Parameters

9.5.1.        Analysis by Route of Administration

9.5.2.        Analysis by Type of Molecule

9.5.3.        Analysis by Therapeutic Indication

9.5.4.        Grid Analysis: Distribution by Therapeutic Indication, Phase of Development and Route of Administration

                

9.6.           Autoinjector Combination Products: List of Developers

9.6.1.        Analysis by Year of Establishment

9.6.2.        Analysis by Company Size

9.6.3.        Analysis by Location of Headquarters

                

10.            CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS

10.1.         Chapter Overview

10.2.         Marketed / Pipeline Drugs Being Evaluated with Autoinjectors

10.3.         Case Study I: Anaphylaxis

10.3.1.       Overview and Epidemiology

10.3.2.       Adrenaline: Mechanism of Action

10.3.3.       History of Development

 

10.3.4.       Marketed Adrenaline / Epinephrine Autoinjectors

10.3.4.1.    Adrenaclick

10.3.4.2.    Allerject / Auvi-Q (Formerly called e-cue)

10.3.4.3.    Anapen

10.3.4.4.    Emerade

10.3.4.5.    EpiPen / EpiPen Jr

10.3.4.6.    Jext

10.3.4.7.    EpiPen / EpiPen Jr

 

10.3.5.       Adrenaline / Epinephrine Autoinjectors Under Development

10.3.5.1.    EpiQ

10.3.5.2.    ANDIPen

10.3.5.3.    MiniEpi

10.3.5.4.    Zeneo Adrenaline

 

10.3.6.       Other Dosage Forms

10.3.7.       Historical Sales of Approved Drugs / Autoinjectors

                

10.4.         Case Study II: Multiple Sclerosis

10.4.1.       Overview and Epidemiology

10.4.2.       Interferon β-1a

10.4.3.       Interferon β-1b

10.4.4.       Interferons: Mechanism of Action

10.4.5.       History of Development

 

10.4.6.       Interferon β-1a Autoinjectors

10.4.6.1.    Avonex Pen

10.4.6.2.    PLEGRIDY Pen

10.4.6.3.    Rebif Rebidose

10.4.6.4.    RebiSmart

10.4.6.5.    Rebiject II

10.4.6.6.    ReciGen Physioject

 

10.4.7.       Interferon β-1b Autoinjectors

10.4.7.1.    BETACONNECT

10.4.7.2.    BETAJECT Comfort / Betacomfort

10.4.7.3.    Betaject Lite

10.4.7.4.    ExtaviJect 30G / ExtaviPro 30G

 

10.4.8.       Other Marketed Autoinjectors

10.4.8.1.    Cinnomer40 Physioject

10.4.8.2.    CSYNC Autoinjector

10.4.8.3.    WhisperJECT

10.4.8.4.    Remurel Autoxon

 

10.4.9.       Other Dosage Forms

10.4.10.     Historical Sales of Approved Drugs / Autoinjectors

10.4.10.1.  Interferon β-1a

10.4.10.2.  Interferon β-1b

 

10.5.         Case Study III: Migraine

10.5.1.       Overview and Epidemiology

10.5.2.       Sumatriptan Succinate: Mechanism of Action

10.5.3.       History of Development

10.5.4.       Marketed Autoinjectors

10.5.4.1.    ALSUMA

10.5.4.2.    IMITREX STATdose Pen

10.5.4.3.    Zembrace SymTouch

10.5.4.4.    Aimovig SureClick Autoinjector

10.5.4.5.    Emgality Prefilled Pen

 

10.5.5.       Other Dosage Forms

10.5.6.       Historical Sales of Approved Drugs / Autoinjectors

                

10.6.         Case Study IV: Rheumatoid Arthritis

10.6.1.       Overview and Epidemiology

10.6.2.       History of Development

 

10.6.3.       Marketed Autoinjectors for Rheumatoid Arthritis

10.6.3.1.    Actemra

10.6.3.2.    CIMZIA AutoClicks Prefilled Pen

10.6.3.3.    Enbrel SureClick

10.6.3.4.    Hulio Prefilled Pen

10.6.3.5.    HUMIRA Pen

10.6.3.6.    ORENCIA ClickJect

10.6.3.7.    OTREXUP

10.6.3.8.    Rasuvo Autoinjector

10.6.3.9.    SIMPONI SmartJect Autoinjector

10.6.3.10.  KEVZARA Prefilled Pen

10.6.3.11.  IMRALDI Prefilled Pen

 

10.6.4.       Historical Sales of Approved Drugs / Autoinjectors

                

11.            LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS

11.1.         Chapter Overview

11.2.         Methodology and Key Parameters

11.3.         Marketed Drug Candidates for Delivery via Autoinjectors

11.3.1.       Most Likely Drug Candidates

11.3.2.       Likely Drug Candidates

11.3.3.       Less Likely Drug Candidates

11.3.4.       Unlikely Drug Candidates

 

11.4.         Clinical Drug Candidates for Delivery via Autoinjectors

11.4.1.       Most Likely Drug Candidates

11.4.2.       Likely Drug Candidates

11.4.3.       Less Likely Drug Candidates

11.4.4.       Unlikely Drug Candidates

                

12.            KEY PLAYERS

12.1.         Chapter Overview

12.2.         Antares Pharma

12.2.1.       Company Overview

12.2.2.       Financial Information

12.2.3.       Product Portfolio

12.2.3.1.    Autoinjectors: Product Details

12.2.3.1.1. Vibex

12.2.3.1.2. QuickShot

12.2.3.1.3. BigShot

 

12.2.4.       Collaborators

12.2.4.1.    Teva Pharmaceutical

12.2.4.2.    Ferring Pharmaceuticals

12.2.4.3.    AMAG Pharmaceuticals

12.2.4.4.    JCR Pharmaceuticals

12.2.4.5.    Pfizer

12.2.4.6.    Idorsia Pharmaceuticals

 

12.2.5.       Recent Developments and Future Outlook

                

12.3          Consort Medical (Previously Bespak)

12.3.1.       Company Overview

12.3.2.       Financial Information

12.3.3.       Technology Overview

12.3.4.       Product Portfolio

12.3.4.1.    Autoinjectors: Product Details

12.3.4.1.1. Syrina

12.3.4.1.2. OTS Autoinjector

12.3.4.1.3. Viscala Autoinjector

 

12.3.5.       Collaborators

12.3.5.1.    Aesica Pharmaceuticals

12.3.5.2.    Undisclosed Global Biopharmaceutical Company

12.3.5.3.    Regeneron Pharmaceuticals

 

12.3.6.       Recent Developments and Future Outlook

                

12.4.         DALI Medical Devices

12.4.1.       Company Overview

12.4.2.       Product Portfolio

12.4.2.1.    Autoinjectors: Product Details

12.4.2.1.1. SAN-L

12.4.2.1.2. SAN-P

12.4.2.1.3. SAN-DV

12.4.2.1.4. SAN-DV Pro

12.2.2.1.5. SAN-Light

 

12.4.3.       Collaborators

12.4.3.1.    Elcam Drug Delivery Devices

 

12.4.4.       Recent Developments and Future Outlook

                

12.5.         Elcam Medical (E3D Elcam Drug Delivery Devices)

12.5.1.       Company Overview

12.5.2.       Product Portfolio

12.5.2.1.    Autoinjectors: Product Details

12.5.2.1.1. Flexi-Q Disposable Autoinjectors

12.5.2.1.1.1.      Flexi-Q PFS

12.5.2.1.1.2.      Flexi-Q HV

12.5.2.1.1.3.      Flexi -Q DV

 

12.5.2.1.2. Flexi-Q Reusable Autoinjectors

12.5.2.1.2.1.      Flexi-Q mMU

12.5.2.1.2.2.      Flexi-Q eMU-C / P

12.5.2.1.2.3.      Flexi-Q EAI

 

12.5.3.       Comparison of Elcam Medical Autoinjectors

12.5.4.       Collaborators

12.5.4.1.    DALI Medical Devices

 

12.5.5.       Recent Developments and Future Outlook

                

12.6.         Jiangsu Delfu Medical Devices

12.6.1.       Company Overview

12.6.2.       Financial Information

12.6.3.       Product Portfolio

12.6.3.1.    Autoinjectors: Overview and Specifications

12.6.3.1.1. Components of Delfu Autoinjectors

12.6.3.1.2. Applications of Delfu Autoinjectors

12.6.3.1.3. Features of Delfu Autoinjectors

12.6.3.1.4. Advantages of Delfu Autoinjectors

12.6.3.1.5. Specifications of Delfu Autoinjectors

 

12.6.3.2.    Autoinjectors: Product Details

12.6.3.2.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector

12.6.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector

12.6.3.2.3. DZ-IA Auto Injector Pen

12.6.3.2.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens

12.6.3.2.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen

12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors

12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen

12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen

12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen

12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen

 

12.6.4.       Recent Developments and Future Outlook

                

12.7.         Oval Medical Technologies

12.7.1.       Company Overview

12.7.2.       Product Portfolio

12.7.2.1.    Autoinjectors: Product Details

12.7.2.1.1  ArQ

12.7.2.1.2  ArQ - Bios

12.7.2.1.3  ArQ - Tempo

12.7.2.1.4  ArQ - Vita

 

12.7.3.       Collaborators

12.7.3.1.    SOLIZE

 

12.7.4.       Recent Developments and Future Outlook

                

12.8.         Owen Mumford

12.8.1.       Company Overview

12.8.2.       Product Portfolio

12.8.2.1.    Autoinjectors: Product Details

12.8.2.1.1. Autoject Micro

12.8.2.1.2. Autoject 2

12.8.2.1.3. Autoject Mini

12.8.2.1.4. Autoject Visco

12.8.2.1.5. UniSafe Auto-injector

12.8.2.1.6. UniSafe Connected Auto-injector

 

12.8.3.       Collaborators

12.8.3.1.    Nipro

12.8.3.2.    Sanofi Aventis

 

12.8.4.       Recent Developments and Future Outlook

                

12.9.         SHL Group

12.9.1.       Company Overview

12.9.2.       Product Portfolio

12.9.2.1.    Two-Step Disposable Autoinjectors: Product Details

12.9.2.1.1  Amber (Pushclick Technology)

12.9.2.1.2. Molly

12.9.2.1.3. Molly RNS

12.9.2.1.4. Molly 2.25

12.9.2.1.5. Rotaject

12.9.2.1.6. Bertha

12.9.2.1.7. DAI 2

12.9.2.1.8. Maggie

12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors

 

12.9.2.2.    Three-Step Disposable Autoinjectors: Product Details

12.9.2.2.1. DAI

12.9.2.2.2. SDI-MIX+NIT (Needle Isolation Technology and Twist and Mix Mechanism)

12.9.2.2.3. VSDI+NIT

12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors

12.9.2.3.    PPI Injector (Rotaject Pressure Release Technology)

 

12.9.4.       Collaborators

12.9.4.1.    Schreiner MediPharm

12.9.4.2.    QuiO

 

12.9.5.       Recent Developments and Future Outlook

                

12.10.        Union Medico

12.10.1.     Company Overview

12.10.2.     Technology Overview

12.10.3.     Product Portfolio

12.10.3.1.  Autoinjectors: Product Details

12.10.3.1.1  45˚ Autoinjector

12.10.3.1.2  45˚/ S Autoinjector

12.10.3.1.3  45˚/ M Autoinjector

12.10.3.1.4  45˚/ R Autoinjector

12.10.3.1.5  Comparison of 45˚ Autoinjectors

12.10.3.1.6  90˚Autoinjector

12.10.3.1.7  90˚/ S Autoinjector

12.10.3.1.8  90˚/ M Autoinjector

12.10.3.1.9  90˚/ XL Autoinjector

12.10.3.1.10      SuperGrip Autoinjector

12.10.3.1.11      Exclusive Autoinjector

12.10.3.1.12      Comparison of 90˚ Autoinjectors

 

12.10.4.     Recent Developments and Future Outlook

                

12.11.        Ypsomed

12.11.1.     Company Overview

12.11.2.     Financial Information

12.11.3.     Product Portfolio

12.11.3.1.  Autoinjectors: Product details

12.11.3.1.1. YpsoMate ,YpsoMate 2.25 and YpsoMate 2.25Pro

12.11.3.1.2. VarioJect

12.11.3.1.3. LyoTwist Trio, LyoTwist Trio S, LyoTwist Vario and LyoTwist Vario S

12.11.3.1.4. Comparison of Autoinjectors

 

12.11.4.     Collaborators

12.11.4.1.  Royal Philips

 

12.11.5.     Recent Developments and Future Outlook

                

13.            EMERGING PLAYERS

13.1.         Chapter Overview

13.2.         AktiVax

13.3.         Amneal Pharmaceuticals

13.4.         kaléo

13.5.         Nemera

13.6.         Nuance Designs

13.7.         Windgap Medical

13.8.         Xeris Pharmaceuticals

13.9.         Zion Clinical Pharmacy

                

14.            KOL ANALYSIS

14.1.         Chapter Overview

14.2.         Methodology

14.3.         KOL Analysis: Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials

14.3.1.       Geographical Distribution of KOLs

14.3.2.       KOL Benchmarking

 

14.3.         KOL Analysis: Patent Assignees

14.3.1.       Geographical Distribution of KOLs

                

15.            SWOT ANALYSIS

15.1.         Chapter Overview

15.2.         Strengths

15.3.         Weaknesses

15.4.         Opportunities

15.5.         Threats

15.6.         Concluding Remarks

                

16.            CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS

16.1.         Chapter Overview

16.2.         Challenges Associated with Medical Device Manufacturing

16.3.         Role of CMOs in Medical Device Manufacturing

16.4.         Services Offered by Medical Device CMOs

16.5.         Advantages Offered by Medical Device CMOs

16.6.         Risks Associated with Outsourcing to CMOs

16.7.         Drug Delivery Service Providers

16.7.1.       Analysis by Year of Establishment

16.7.2.       Analysis by Company Size

16.7.3.       Analysis by Geography

16.7.4.       Analysis by Types of Services

16.8.         Concluding Remarks

 

17.            MARKET SIZING AND OPPORTUNITY ANALYSIS

17.1.         Chapter Overview

17.2.         Forecast Methodology and Key Assumptions

17.3.         Global Autoinjectors Market, 2020-2030 (By Value)

17.3.1.       Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Value)

17.3.2.       Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.3.       Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.4.       Autoinjectors Market in North America, 2020-2030 (By Value)

17.3.4.1.    Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Value)

17.3.4.2.    Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.4.3.    Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.5.       Autoinjectors Market in Europe, 2020-2030 (By Value)

17.3.5.1.    Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Value)

17.3.5.2.    Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.5.3.    Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.6.       Autoinjectors Market in Asia Pacific, 2020-2030 (By Value)

17.3.6.1.    Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.3.6.2.    Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.6.3.    Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.3.7.       Autoinjectors Market in Rest of the World, 2020-2030 (By Value)

17.3.7.1.    Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.3.7.2.    Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.3.7.3.    Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.4.         Global Autoinjectors Market, 2020-2030 (By Volume)

17.4.1.       Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Volume)

17.4.2.       Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Volume)

17.4.3.       Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.4.4.       Autoinjectors Market in North America, 2020-2030 (By Volume)

17.3.4.1.    Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Volume)

17.3.4.2.    Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.4.3.    Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.3.5.       Autoinjectors Market in Europe, 2020-2030 (By Volume)

17.3.5.1.    Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.3.5.2.    Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.5.3.    Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.3.6.       Autoinjectors Market in Asia Pacific, 2020-2030 (By Volume)

17.3.6.1.    Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.3.6.2.    Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.6.3.    Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.3.7.       Autoinjectors Market in Rest of the World, 2020-2030 (By Volume)

17.3.7.1.    Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.3.7.2.    Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.3.7.3.    Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.5.         Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Value)

17.5.1.       Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Value)

17.5.1.1.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Value)

17.5.1.2.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.1.3.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.5.2.       Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Value)

17.5.2.1.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Value)

17.5.2.2.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.2.3.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.5.3.       Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Value)

17.5.3.1.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.5.3.2.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.3.3.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.5.4.       Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Value)

17.5.4.1.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.5.4.2.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.5.4.3.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.6.         Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Volume)

17.6.1.       Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Volume)

17.6.1.1.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Volume)

17.6.1.2.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.1.3.    Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.6.2.       Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Volume)

17.6.2.1.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.6.2.2.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.2.3.    Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.6.3.       Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Volume)

17.6.3.1.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.6.3.2.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.3.3.    Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.6.4.       Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Volume)

17.6.4.1.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.6.4.2.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.6.4.3.    Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.7.         Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Value)

17.7.1.       Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Value)

17.7.1.1.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Value)

17.7.1.2.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.1.3.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.7.2.       Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Value)

17.7.2.1.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Value)

17.7.2.2.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.2.3.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.7.3.       Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Value)

17.7.3.1.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.7.3.2.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.3.3.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.7.4.       Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Value)

17.7.4.1.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.7.4.2.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.7.4.3.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.8.         Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Volume)

17.8.1.       Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Volume)

17.8.1.1.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Volume)

17.8.1.2.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.1.3.    Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.8.2.       Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Volume)

17.8.2.1.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.8.2.2.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.2.3.    Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.8.3.       Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Volume)

17.8.3.1.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.8.3.2.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.3.3.    Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.8.4.       Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Volume)

17.8.4.1.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.8.4.2.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.8.4.3.    Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.9.         Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Value)

17.9.1.       Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Value)

17.9.1.1.    Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Value)

17.9.1.2.    Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.1.3.    Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.9.2.       Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Value)

17.9.2.1.    Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Value)

17.9.2.2.    Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.2.3.    Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.9.3.       Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Value)

17.9.3.1.    Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.9.3.2.    Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.3.3.    Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.9.4.       Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Value)

17.9.4.1.    Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.9.4.2.    Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.9.4.3.    Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.10.        Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Volume)

17.10.1.     Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Volume)

17.10.1.1.  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Volume)

17.10.1.2.  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.1.3.  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.10.2.     Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Volume)

17.10.2.1.  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.10.2.2.  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.2.3.  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.10.3.     Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Volume)

17.10.3.1.  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.10.3.2.  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.3.3.  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.10.4.     Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Volume)

17.10.4.1.  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.10.4.2.  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.10.4.3.  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.11.        Global Autoinjectors Market for Migraine, 2020-2030 (By Value)

17.11.1.     Autoinjectors Market for Migraine in North America, 2020-2030 (By Value)

17.11.1.1.  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Value)

17.11.1.2.  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.1.3.  Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.11.2.     Autoinjectors Market for Migraine in Europe, 2020-2030 (By Value)

17.11.2.1.  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Value)

17.11.2.2.  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.2.3.  Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.11.3.     Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Value)

17.11.3.1.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.11.3.2.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.3.3.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.11.4.     Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Value)

17.11.4.1.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.11.4.2.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.11.4.3.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.12.        Global Autoinjectors Market for Migraine, 2020-2030 (By Volume)

17.12.1.     Autoinjectors Market for Migraine in North America, 2020-2030 (By Volume)

17.12.1.1.  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Volume)

17.12.1.2.  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.1.3.  Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.12.2.     Autoinjectors Market for Migraine in Europe, 2020-2030 (By Volume)

17.12.2.1.  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.12.2.2.  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.2.3.  Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.12.3.     Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Volume)

17.12.3.1.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.12.3.2.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.3.3.  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.12.4.     Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Volume)

17.12.4.1.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.12.4.2.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.12.4.3.  Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

17.13.        Global Autoinjectors Market for Diabetes, 2020-2030 (By Value)

17.13.1.     Autoinjectors Market for Diabetes in North America, 2020-2030 (By Value)

17.13.1.1.  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Value)

17.13.1.2.  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.1.3.  Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.13.2.     Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Value)

17.13.2.1.  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Value)

17.13.2.2.  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.2.3.  Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.13.3.     Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Value)

17.13.3.1.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.13.3.2.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.3.3.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.13.4.     Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Value)

17.13.4.1.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.13.4.2.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.13.4.3.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

                

17.14.        Global Autoinjectors Market for Diabetes, 2020-2030 (By Volume)

17.14.1.     Autoinjectors Market for Diabetes in North America, 2020-2030 (By Volume)

17.14.1.1.  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Volume)

17.14.1.2.  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.1.3.  Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.14.2.     Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Volume)

17.14.2.1.  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.14.2.2.  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.2.3.  Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.14.3.     Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Volume)

17.14.3.1.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.14.3.2.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.3.3.  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.14.4.     Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Volume)

17.14.4.1.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.14.4.2.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.14.4.3.  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.15.        Global Autoinjectors Market for Other Indications, 2020-2030 (By Value)

17.15.2.     Autoinjectors Market for Other Indications in North America, 2020-2030 (By Value)

17.15.2.1.  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Value)

17.15.2.2.  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.2.3.  Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.15.3.     Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Value)

17.15.3.1.  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Value)

17.15.3.2.  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.3.3.  Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.15.4.     Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Value)

17.15.4.1.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

17.15.4.2.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.4.3.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.15.5.     Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Value)

17.15.5.1.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Value)

17.15.5.2.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)

17.15.5.3.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

 

17.16.        Global Autoinjectors Market for Other Indications, 2020-2030 (By Volume)

17.16.1.     Autoinjectors Market for Other Indications in North America, 2020-2030 (By Volume)

17.16.1.1.  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Volume)

17.16.1.2.  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.1.3.  Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.16.2.     Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Volume)

17.16.2.1.  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Volume)

17.16.2.2.  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.2.3.  Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.16.3.     Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Volume)

17.16.3.1.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)

17.16.3.2.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.3.3.  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

 

17.16.4.     Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Volume)

17.16.4.1.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)

17.16.4.2.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)

17.16.4.3.  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

                

18.            CONCLUSION

18.1.         Rising Incidence of Chronic Illnesses had Created a Growing Preference for Devices that Enable Self-Medication

18.2.         Given their Numerous Benefits, Autoinjector have Emerged as Potent Drug Delivery Tools

18.3.         Several Combination Products Have Already been Approved, while Many are Under Development

18.4.         Majority of the Available Products are Disposable; However, Reusable Devices are Gradually Gaining Popularity

18.5.         Ongoing Research Efforts Have Resulted in the Introduction of Robust Technology Platforms, Enabling the Incorporation of Novel and Advanced Features

18.6.         The Market is Expected to Evolve at a Steady Pace with Developed Nations Retaining the Majority Share, Over the Coming Decade

18.7.         Concluding Remarks

                

19.            INTERVIEW TRANSCRIPTS

19.1.         Chapter Overview

19.2.         DALI Medical Devices

19.2.1.       Company Snapshot

19.2.2.       Interview Transcript: David Daily, CEO and Co-Founder

 

19.3.         PHC

19.3.1.       Company Snapshot

19.3.2.       Interview Transcript: Douglas Marenzi, Managing Director

                

19.4.         Elcam Medical

19.4.1.       Company Snapshot

19.4.2.       Interview Transcript: Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices

 

19.5.         IDEO

19.5.1.       Company Snapshot

19.5.2.       Interview Transcript: Jesse Fourt, Design Director

 

19.6.         Bill & Melinda Gates Foundation

19.6.1.       Company Snapshot

19.6.2.       Interview Transcript: Dennis Lee, Senior Program Officer in CMC

                

20.            APPENDIX 1: TABULATED DATA

                

21.            APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com